Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Bausch + Lomb just swapped out its CEO — and the timing raises big questions. Thomas J. Appio replaced Brent Saunders as interim CEO just before a strong earnings report, suggesting parent company Bausch Health Companies (BHC) is maneuvering for control. With $21 billion in debt and activist investor John Paulson holding stakes in both companies, a sale of B+L may be in the cards.
Bausch + Lomb (B+L) made a notable leadership move on Oct. 12, naming Thomas J. Appio as interim CEO and parting ways with Brent Saunders — right before what's expected to be a strong Q3 earnings report. The announcement, made during the American Academy of Ophthalmology's annual meeting, drew significant attention across the eye care world. Observers see the move as parent company Bausch Health Companies (BHC) tightening its grip on B+L ahead of a potential major transaction.
The backstory matters here. BHC owns roughly 89% of B+L following its IPO about four years ago. In August, BHC replaced four B+L board members with more aligned directors and elected Appio as chairman — signaling that a leadership overhaul was coming. Now, with Saunders out, BHC has full control of B+L's direction.
By the Numbers:
Why it matters: A sale of B+L — valued at nearly $11 billion — could significantly ease BHC's massive debt burden. With Paulson's influence on both boards and Saunders now out of the picture, the ophthalmology industry should brace for more major announcements.
